Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.14 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

gi dynamics inc-cdi (GIDYL) Snapshot

Open
$0.14
Previous Close
$0.14
Day High
$0.14
Day Low
$0.14
52 Week High
06/26/14 - $0.67
52 Week Low
10/21/14 - $0.10
Market Cap
66.4M
Average Volume 10 Days
14.2K
EPS TTM
--
Shares Outstanding
474.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GI DYNAMICS INC-CDI (GIDYL)

Related News

No related news articles were found.

gi dynamics inc-cdi (GIDYL) Related Businessweek News

No Related Businessweek News Found

gi dynamics inc-cdi (GIDYL) Details

GI Dynamics, Inc. designs, develops, and markets medical devices for non-surgical approaches in the United States. It offers EndoBarrier, a non-surgical, non-pharmaceutical therapy for the treatment of type 2 diabetes and/or obesity. The company sells its product in Europe, South America, and Australia. GI Dynamics, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

Founded in 2003

gi dynamics inc-cdi (GIDYL) Top Compensated Officers

Chief Medical Officer
Total Annual Compensation: $220.0K
Compensation as of Fiscal Year 2013.

gi dynamics inc-cdi (GIDYL) Key Developments

GI Dynamics, Inc. Announces U.S. Food and Drug Administration Placed Hold on Enrollment in its Pivotal Clinical Trial of Endobarrier Therapy in U.S

GI Dynamics, Inc. announced that the U.S. Food and Drug Administration (FDA) has placed a hold on enrollment in the company's ongoing pivotal clinical trial of EndoBarrier Therapy (the ENDO Trial) in the U.S. Monitoring and data collection involving patients currently enrolled in the ENDO Trial will continue. The decision to hold further enrollment results from 4 cases of a bacterial infection of the liver, known as hepatic abscess, among the 325 subjects currently enrolled in the ENDO Trial. Hepatic abscess is a known event related to the use of EndoBarrier but has recently presented at a higher than anticipated rate in the ENDO Trial. The FDA has therefore requested additional information to further assess the risk: benefit profile of the EndoBarrier in the ENDO Trial. The company has already implemented several risk mitigation strategies in the ENDO Trial and is expeditiously working to submit the requested information to the FDA for their review in an effort to resume enrollment.

GI Dynamics, Inc. - Special Call

To update investors regarding the ENDO Trial

GI Dynamics, Inc. Reports Unaudited Consolidated Earnings Results for the Year Ended December 31, 2014

GI Dynamics, Inc. reported unaudited consolidated earnings results for the year ended December 31, 2014. For the year, the company reported loss from operations of $48,190,000 against $34,856,000 a year ago. Loss before income tax expense was $48,135,000 against $35,482,000 a year ago. Basic and diluted net loss per commons hare was $0.54 against $0.53 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GIDYL:US $0.14 USD 0.00

GIDYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GIDYL.
View Industry Companies
 

Industry Analysis

GIDYL

Industry Average

Valuation GIDYL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 23.5x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GI DYNAMICS INC-CDI, please visit www.gidynamics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.